[1] WICKENHAUSER C. WHO classification of myeloid neoplasms[J]. Pathol, 2018,39(12):315-318. [2] 罗源,王春美,盛光耀. 复发儿童急性淋巴细胞白血病58例临床分析[J]. 中国小儿血液与肿瘤杂志,2016,21(4):201-206. [3] JALAL S D, AI-ALLAWI NAS, AI DOSKI AA S. Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients [J]. Int J Lab Hematol, 2017, 39(6):625-632. [4] 中华医学会儿科学分会血液学组,中华儿科杂志编辑委员会.儿童急性淋巴细胞白血病诊疗建议(第四次修订草案) [J]. 中华儿科杂志,2014,52(9):641-644. [5] 陈晓娟,邹尧,刘晓明,等. CCLLG-ALL2008方案治疗不同分子生物学特征儿童急性淋巴细胞白血病的长期疗效分析[J]. 中国当代儿科杂志,2019,21(9):890-893. [6] BING C, LU J, MENGLING Z, et al. Identification of fusion genes and characterization of transcriptomeeature in T-cell Acute Lymphoblastic Leukemia[J]. Proc Natl Acad Sci USA, 2018, 115(2):373-378. [7] 贺晶,刘伶. NUDT15基因型对儿童急性淋巴细胞白血病6-MP个体化治疗的影响[J]. 中国当代儿科杂志,2019,21(1):100-104. [8] 赵莉,高吉照,李艳,等. 50例儿童急性淋巴细胞白血病免疫分型、染色体核型及融合基因与预后分析[J]. 中国小儿血液与肿瘤杂志,2019,24(2):95-99. [9] JIN Y, WANG X, HU S, et al. Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing[J]. Cancer Med, 2016, 5(2):337-351. [10] 张建平,杨君芳,王芳,等. 1 392例初诊儿童急性淋巴细胞白血病患者36种融合基因筛查分析[J]. 临床与病理杂志,2018,38(5):956-959. [11] 谢淑佩,段炤,陈媛媛,等. TEL-AML1融合基因的表达与儿童急性淋巴细胞白血病的疗效及预后相关性研究[J]. 海南医学,2012,23(22):4-6. [12] 唐燕萍,蔡政民,唐亚梅, 等. 表达融合基因的急性B淋巴细胞白血病患者形态学和免疫表型特点[J]. 现代肿瘤医学,2017,25(7):1097-1100. [13] JIANG Z, DENG M, WEI X, et al. Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized[J]. J Hematol Oncol, 2016, 9(1) : 94-101. [14] 徐一卓,王西阁,陈力溶. 河南地区248例儿童急性淋巴细胞白血病融合基因类型分析[J]. 郑州大学学报(医学版),2019,54(3):470-473. [15] 刘芳,高丽,于力. 急性淋巴细胞白血病融合基因研究进展[J]. 中华保健医学杂志,2013,15(1):70-72. [16] VITALE A, GUARINI A, ARIOLA C, et al. Adult T cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMALAL 496 protocol[J]. Blood, 2006, 107(2): 473-479. |